Knowing that a significant percentage of prostate malignancy harbours the TMPRSS2-ERG junction oncogene, our aim is to introduce a new potential therapeutic approach by siRNA targeting TMPRSS2-ERG junction oncogene in patients with prostate cancer. Here, ERG is linked to prostate cancer.